• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服抗凝剂联合双重抗血小板治疗预防急性缺血性卒中失败1例

A Case of Failed Dual Antiplatelet Therapy With Oral Anticoagulant in the Prevention of Acute Ischemic Stroke.

作者信息

Amoda Oluyemisi, A Elmarie, Uwagbale Ese

机构信息

Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.

出版信息

Cureus. 2021 Jun 25;13(6):e15915. doi: 10.7759/cureus.15915. eCollection 2021 Jun.

DOI:10.7759/cureus.15915
PMID:34322355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8310612/
Abstract

Cerebrovascular accidents (CVA) or strokes cause focal neurological deficits, which may be due to rupture or occlusion of blood vessels supplying areas of the brain. Atrial fibrillation (AF) is an independent and significant risk factor for ischemic CVA, mainly via the embolic pathway. This is evident as newly diagnosed patients with AF are typically started on anticoagulation therapy if their CHA2DS2-VASc score is equal to or greater than two. Furthermore, ischemic CVA may occur as a thrombotic phenomenon due to significant vessel atherosclerotic disease involving plaque ulceration and rupture. Such a phenomenon may be curtailed with antiplatelet therapy in at-risk patient populations, particularly as a form of secondary prevention. This case highlights the unfortunate incidence of an ischemic CVA in a patient using dual antiplatelet therapy (DAPT) and anticoagulation.

摘要

脑血管意外(CVA)或中风会导致局灶性神经功能缺损,这可能是由于供应脑区的血管破裂或阻塞所致。心房颤动(AF)是缺血性CVA的一个独立且重要的危险因素,主要通过栓塞途径。这一点很明显,因为新诊断的AF患者如果其CHA2DS2-VASc评分等于或大于2,通常会开始接受抗凝治疗。此外,缺血性CVA可能是由于涉及斑块溃疡和破裂的严重血管动脉粥样硬化疾病而出现的血栓形成现象。在高危患者群体中,这种现象可以通过抗血小板治疗得到缓解,特别是作为二级预防的一种形式。本病例突出了一名正在使用双联抗血小板治疗(DAPT)和抗凝治疗的患者发生缺血性CVA的不幸事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106a/8310612/ff93bcb3a2fe/cureus-0013-00000015915-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106a/8310612/a1db07f4b5f7/cureus-0013-00000015915-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106a/8310612/ff93bcb3a2fe/cureus-0013-00000015915-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106a/8310612/a1db07f4b5f7/cureus-0013-00000015915-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/106a/8310612/ff93bcb3a2fe/cureus-0013-00000015915-i02.jpg

相似文献

1
A Case of Failed Dual Antiplatelet Therapy With Oral Anticoagulant in the Prevention of Acute Ischemic Stroke.口服抗凝剂联合双重抗血小板治疗预防急性缺血性卒中失败1例
Cureus. 2021 Jun 25;13(6):e15915. doi: 10.7759/cureus.15915. eCollection 2021 Jun.
2
Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?对于 CHA2DS2-VASc 评分(除性别以外)有 1 个额外危险因素的房颤患者,是否应接受口服抗凝治疗?
J Am Coll Cardiol. 2015 Feb 24;65(7):635-42. doi: 10.1016/j.jacc.2014.11.046.
3
The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.抗凝和抗血小板治疗对低风险房颤患者的基于人群的长期影响。
Am J Cardiol. 2017 Jul 1;120(1):75-82. doi: 10.1016/j.amjcard.2017.03.256. Epub 2017 Apr 12.
4
ATRIAL FIBRILLATION AND STROKE PREVENTION PRACTICES IN PATIENTS WITH CANDIDACY FOR ANTICOAGULATION THERAPY.有抗凝治疗适应证患者的心房颤动与卒中预防实践
J Ayub Med Coll Abbottabad. 2015 Jul-Sep;27(3):669-72.
5
Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.房颤合并冠心病患者的抗血栓治疗。
BMC Cardiovasc Disord. 2020 Jul 6;20(1):323. doi: 10.1186/s12872-020-01609-8.
6
Incidence and Predictors of 30-day Acute Cerebrovascular Accidents Post Atrial Fibrillation Catheter Ablation (From the Nationwide Readmissions Database).心房颤动导管消融术后 30 天内急性脑血管意外的发生率及预测因素(来自全国再入院数据库)。
Am J Cardiol. 2021 Jan 1;138:61-65. doi: 10.1016/j.amjcard.2020.10.020. Epub 2020 Oct 13.
7
Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.经皮左心耳封堵术预防高卒中及出血风险房颤患者血栓栓塞事件的疗效与安全性。
Clin Res Cardiol. 2016 Mar;105(3):225-9. doi: 10.1007/s00392-015-0910-8. Epub 2015 Aug 30.
8
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.新旧抗凝药物在高危心房颤动中预防缺血性卒中失败:一例病例报告。
Minerva Cardioangiol. 2016 Aug;64(4):494-6.
9
Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis.需要透析的终末期肾病房颤患者缺血性卒中的发病率及预测
Heart Rhythm. 2014 Oct;11(10):1752-9. doi: 10.1016/j.hrthm.2014.06.021. Epub 2014 Jun 18.
10
Dual antiplatelet therapy after percutaneous left atrial appendage occlusion: single center experience with the Amplatzer Cardiac Plug.经皮左心耳封堵术后的双联抗血小板治疗:使用Amplatzer心脏封堵器的单中心经验
Acta Cardiol. 2019 Feb;74(1):74-81. doi: 10.1080/00015385.2018.1455946. Epub 2018 Apr 1.

本文引用的文献

1
Stroke Prevention in Atrial Fibrillation: Looking Forward.心房颤动的卒中预防:展望未来。
Circulation. 2020 Dec 15;142(24):2371-2388. doi: 10.1161/CIRCULATIONAHA.120.049768. Epub 2020 Dec 14.
2
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.心房颤动患者的早期节律控制治疗。
N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29.
3
Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
急性缺血性卒中和短暂性脑缺血发作后预防复发的三联抗血小板治疗与指南推荐抗血小板治疗的随机对照试验(TARDIS RCT)。
Health Technol Assess. 2018 Aug;22(48):1-76. doi: 10.3310/hta22480.
4
AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score.心房颤动与静脉血栓栓塞——病理生理学、风险评估及CHADS-VASc评分
J Atr Fibrillation. 2012 Oct 6;5(3):649. doi: 10.4022/jafib.649. eCollection 2012 Oct-Nov.
5
Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.甲氧苄啶/磺胺甲恶唑相关肝毒性的多中心研究:接受耶氏肺孢子菌肺炎治疗的HIV感染患者中的发病率及相关因素
PLoS One. 2014 Sep 3;9(9):e106141. doi: 10.1371/journal.pone.0106141. eCollection 2014.
6
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.在心房颤动患者中同时使用阿司匹林治疗和口服抗凝治疗的情况及相关风险:来自 Outcomes Registry for Better Informed Treatment of Atrial Fibrillation(ORBIT-AF)登记研究的见解。
Circulation. 2013 Aug 13;128(7):721-8. doi: 10.1161/CIRCULATIONAHA.113.002927. Epub 2013 Jul 16.
7
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
8
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
9
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).根据卒中风险比较口服抗凝药与氯吡格雷加阿司匹林用于心房颤动患者的风险和获益:厄贝沙坦氯吡格雷预防血管事件心房颤动试验(ACTIVE-W)
Stroke. 2008 May;39(5):1482-6. doi: 10.1161/STROKEAHA.107.500199. Epub 2008 Mar 6.
10
A comparison of rate control and rhythm control in patients with atrial fibrillation.心房颤动患者心率控制与节律控制的比较。
N Engl J Med. 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328.